Modeling Pancreatic Cancer Dynamics with Immunotherapy.
This study concludes that mono-immunotherapy is unlikely to control the pancreatic cancer and combined immunotherapies between anti-TGF-[Formula: see text] and adoptive transfers of immune cells can prolong patient survival. We show through numerical explorations that how these two types of immunotherapies are scheduled is important to survival. Applying TGF-[Formula: see text] inhibition first followed by adoptive immune cell transfers can yield better survival outcomes.
PMID: 30843136 [PubMed - as supplied by publisher]
Source: Bulletin of Mathematical Biology - Category: Bioinformatics Authors: Hu X, Ke G, Jang SR Tags: Bull Math Biol Source Type: research
More News: Bioinformatics | Biology | Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Pancreas | Pancreatic Cancer | Study